| Regulatory Rapporteur February 2019 | MEMBERS |
| The CMC section of an EU IMPD: Considerations for US sponsors | MEMBERS |
| The SAKIGAKE framework for regenerative medicines in Japan | MEMBERS |
| Design and optimisation of a quality target product profile for ATMPs | MEMBERS |
| Expedited access of cellular and gene therapy products: The EU versus the US | MEMBERS |
| CAT interested parties meeting – recent developments and updates | MEMBERS |